Indivior Pharmaceuticals, Inc. (INDV) Stock Price & How to Invest

Indivior is a specialty pharmaceutical company that develops and markets treatments for opioid use disorder (OUD) and related conditions. Its flagship product, SUBLOCADE, is a once-monthly long-acting injectable form of buprenorphine that has become the dominant long-acting injectable (LAI) for OUD in the United States, holding roughly a 76% share of that market. The company also sells the sublingual film SUBOXONE (now facing generic competition), the opioid overdose reversal agent OPVEE (nalmefene nasal spray), and PERSERIS for schizophrenia. Indivior historically listed in London but shifted its primary listing to the Nasdaq, and it trades under the ticker INDV.

The investment picture is defined by concentration and transition. SUBLOCADE now drives the large majority of growth, with Q1 2026 SUBLOCADE net revenue of roughly $232 million (up about 32% year over year) helping total net revenue reach roughly $317 million. Management raised full-year 2026 guidance to roughly $1.215 to $1.285 billion in net revenue and roughly $620 to $660 million in adjusted EBITDA, reflecting expanding margins. Against a market capitalization of roughly $4.8 billion, INDV is valued as a mid-cap pharma whose thesis hinges on SUBLOCADE sustaining growth while legacy film revenue erodes and litigation overhangs recede.

Indivior is highly concentrated in a single product, so any slowdown in SUBLOCADE adoption, pricing pressure, or competitive entry (for example from Alkermes VIVITROL or Camurus and Braeburn's BRIXADI) would weigh heavily on the whole company. Legacy SUBOXONE film revenue continues to erode as generics take share, and the company has a long history of antitrust and opioid-related litigation and settlements that can resurface as financial and reputational overhangs. Reliance on government and Medicaid channels exposes revenue to reimbursement and budget shifts. Pipeline setbacks, such as the decision to halt INDV-6001 Phase 3, show that non-core bets may not deliver. As a specialty pharma, it also faces regulatory, patent, and manufacturing risks common to the sector.

4 analysts publish price targets on INDV, averaging $49.00 against a $34.56 price as of September 2026, or +41.8%. The published targets run from $43.00 to $53.00, a narrow spread, and the ratings split 4 buy, 0 hold, 0 sell. Over the last six months there have been 0 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full INDV forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Indivior Pharmaceuticals, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. SUBLOCADE market leadership and expansion. SUBLOCADE is the clear leader in long-acting injectable treatment for opioid use disorder, with roughly a 76% U.S. The most optimistic published target, $53.00, assumes this works close to its best case.

The case against. Indivior is highly concentrated in a single product, so any slowdown in SUBLOCADE adoption, pricing pressure, or competitive entry (for example from Alkermes VIVITROL or Camurus and Braeburn's BRIXADI) would weigh heavily on the whole company. The most pessimistic target, $43.00, is roughly what INDV is worth if this bites instead.

Read the full bull and bear case on INDV, including what would have to change to break either one. Walnut is not an investment adviser.

No. Indivior Pharmaceuticals, Inc. (INDV) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Indivior Pharmaceuticals, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$1.2B
• 2026 revenue guidance: ~$1.215B to $1.285B
• SUBLOCADE Q1 2026 net revenue: ~$232M (up ~32% YoY)
• Adjusted EBITDA (2026 guide): ~$620M to $660M
• Market cap: ~$4.8B
• Price / sales (approx): ~4x

Indivior trades as a profitable mid-cap specialty pharma, with a price-to-sales multiple around 4x on roughly $1.2 billion of trailing revenue. The valuation embeds expectations that SUBLOCADE keeps compounding and that margins stay above 50%. Because one product drives most revenue, the multiple is sensitive to any change in SUBLOCADE's growth trajectory.

Other names that sit close to INDV: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get INDV exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so INDV sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where INDV fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

INDV is essentially a single-product growth story: the investment picture rises and falls with SUBLOCADE's ability to keep expanding while patents and generics on legacy products fade.

Whether INDV is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is INDV a buy or a sell?, and where the stock could go from here in the INDV stock forecast.

For income investors, whether INDV pays a dividend and how the payout looks is covered in does INDV pay a dividend? And to weigh INDV against a peer, read the full side-by-side comparisons: INDV vs ALKS and INDV vs CNS.